Exosomes for Hair Loss | How to Read the Evidence Before Paying

Exosome treatments for hair loss remain an emerging area of research. Some small human studies report changes in hair density or thickness, but they do not establish a predictable result, the best treatment schedule or long-term safety for every preparation. The useful starting point is the cause of the hair loss and the evidence for the exact treatment being considered.

At The London PRP Clinic by The Wellness, an enquiry about an emerging treatment can start with the concern itself: a widening parting, recession, reduced density or a change in shedding. An informed plan should explain what is known, what remains uncertain and which established options may fit the diagnosis. It does not have to end with an injection.

What exosomes are

Exosomes are small extracellular vesicles released by cells. They carry material involved in communication between cells. Research has explored whether these signals could influence hair follicles, but a plausible biological mechanism is not proof of useful hair regrowth in a person.

The term does not identify a single standard treatment. Preparations differ in their biological source, processing, contents and dose. Products described as plant-derived vesicles, human-cell-derived exosomes or other cell products should not be treated as interchangeable. Nor does evidence from one preparation establish the effect of another.

Discuss hair loss and treatment evidence or email team@thewellnesslondon.com.

What the clinical evidence shows

A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology included eleven clinical studies: two randomised controlled trials, three retrospective studies, three prospective single-arm studies, one case series and two case reports. The preparations, delivery methods and outcome measures varied. Several studies had important risks of bias, including a lack of control groups or blinding.

The studies reported improvements in at least one hair measure, but this does not establish how much benefit a particular person will see. In an uncontrolled study, changes cannot reliably be separated from the natural course of hair loss, other treatment or differences in measurement. A before-and-after photograph can help record a change without proving what caused it.

A separate 2025 review in Dermatologic Surgery identified nine clinical studies relevant to alopecia, involving 125 people receiving exosome treatment for hair loss. Its authors called for larger, well-designed trials, longer follow-up, consistent manufacturing standards and regulatory oversight. The different study totals reflect different review methods; they should not be added together as though every participant were unique.

The practical conclusion is measured. There is enough interest to justify further research, but not enough consistent evidence to promise reliable regrowth, a fixed number of sessions or superiority over established treatments for every form of hair loss.

Safety needs a separate discussion

The eleven-study review reported mostly mild local reactions and no serious adverse events in its included hair studies. That finding is limited to the people, preparations and follow-up studied. It cannot rule out uncommon complications, delayed harms or risks from a different product.

The Dermatologic Surgery review also noted serious adverse events reported in the broader dermatology literature. Those reports do not establish a numerical risk for scalp treatment, but they are a reason not to describe the entire category as risk-free.

The proposed preparation and procedure both matter. Sourcing, manufacturing, storage, sterility and delivery need consideration alongside the evidence for benefit. Applying a product to the skin, using it around microneedling and injecting it are different procedures. A reassuring result from one method cannot simply be transferred to another.

UK regulation depends on the product and its use

The regulatory position should be explained for the actual product, not inferred from the word "exosome". The MHRA's guidance on what is a medicinal product considers how a product is presented and how it acts. It also makes clear that a substance intended to be injected is not a cosmetic product under the cosmetics definition.

This does not mean that every product described as an exosome has the same classification, or that a product sold as a cosmetic is authorised for injection. Equally, a non-medicinal classification is not an MHRA endorsement of safety or effectiveness. The product, claims, route and applicable legal requirements need to be considered together.

A supplier description or an overseas approval does not by itself establish an appropriate UK treatment pathway. A clinical explanation should identify the exact preparation, intended use and relevant authorisation or other lawful basis without presenting research interest as regulatory approval.

Talk through the evidence before deciding or email team@thewellnesslondon.com.

Diagnosis makes the options clearer

Pattern hair loss, temporary shedding and inflammatory or scarring scalp disease need different approaches. A history and scalp examination help distinguish them. Investigations are useful when there is a clinical reason, rather than being an automatic broad panel for everyone.

The British Association of Dermatologists' information on female pattern hair loss describes diagnosis, treatment options and when blood tests may be appropriate. Its telogen effluvium information explains a different form of shedding that may follow illness, stress, childbirth or other triggers. A change in shedding should not automatically be treated as a reason to purchase a regenerative treatment.

Established options depend on the diagnosis, medical history and personal circumstances. Minoxidil may be relevant for pattern hair loss; other medicines require a separate discussion of suitability and risks. PRP is another distinct procedure, with its own evidence and limits. Having more research than an emerging therapy does not make PRP suitable for every cause of hair loss or guarantee a result.

A worthwhile treatment plan has a review point

A clear consultation should connect the diagnosis, proposed benefit, alternatives and uncertainty. It should also explain how progress will be measured and what happens if there is little improvement. Consistent photographs can support review, provided lighting, position and hair styling are kept comparable.

The proposed total should distinguish the consultation, investigations, treatment and follow-up. A course should not depend on a promise that more sessions will always produce more growth. Deferring a procedure, treating a contributing condition or choosing another option may be the more useful outcome.

An enquiry can begin with how long the change has been present, what you have already tried and what you most want to understand. This helps keep the discussion focused on a useful next step rather than a treatment name.

Enquire about a hair-loss assessment or email team@thewellnesslondon.com.

Frequently asked questions

Are exosomes proven to regrow hair?

Small human studies report improvements in some hair measures, but the evidence is varied and often at risk of bias. It does not establish predictable regrowth for every person, preparation or form of hair loss.

Are exosomes better than PRP?

The evidence reviewed here does not establish that exosomes are consistently better than PRP. They are different procedures, and suitability depends on the diagnosis, the exact preparation and the quality of evidence for the proposed use.

Does no serious harm in a small study prove long-term safety?

No. Small samples and short follow-up may miss uncommon or delayed complications. Findings from one preparation or delivery method cannot establish safety for every product.

Does a cosmetic label mean a product can be injected?

No. MHRA guidance states that an injected substance is not a cosmetic product under the cosmetics definition. The exact product, claims, intended use and relevant legal requirements need separate assessment.

Does everyone need blood tests before hair-loss treatment?

No. The history and scalp examination guide the assessment. Blood tests may help when a deficiency, thyroid problem or another contributing condition is suspected; a broad panel is not automatically needed for everyone.

What should an assessment clarify before treatment?

It should explain the likely diagnosis, reasonable options, expected benefit, risks, uncertainty, proposed total cost and review point. The outcome may be treatment, further assessment, a different approach or no procedure.

Discuss your next step with the clinic or email team@thewellnesslondon.com.

Sources

General information, not individual medical advice. Updated 15 November 2026.

Previous
Previous

Facial PRP Safety | Symptoms That Need Urgent Help After Treatment

Next
Next

PRP Before or After an Infection or Dental Procedure | When to Pause Treatment